Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
Sasai K, Nishimoto S, Shimokawa K, Hisanaga Y, Kitakabu Y, Shibamoto Y, Zhou L, Wang J, Takahashi M, Kagiya T, et al. Sasai K, et al. Among authors: hisanaga y. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1249-54. doi: 10.1016/0360-3016(91)90235-v. Int J Radiat Oncol Biol Phys. 1991. PMID: 1828462
Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers.
Shibamoto Y, Nishimoto S, Shimokawa K, Hisanaga Y, Zhou L, Wang J, Sasai K, Takahashi M, Abe M, Kagiya T. Shibamoto Y, et al. Among authors: hisanaga y. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1045-8. doi: 10.1016/0360-3016(89)90912-7. Int J Radiat Oncol Biol Phys. 1989. PMID: 2703384
Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T. Toyoda H, et al. Among authors: hisanaga y. Oncology. 2001;61(2):134-42. doi: 10.1159/000055364. Oncology. 2001. PMID: 11528252 Clinical Trial.
Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Nakano S, Arakawa T. Toyoda H, et al. Among authors: hisanaga y. Liver Int. 2009 Jan;29(1):120-5. doi: 10.1111/j.1478-3231.2008.01736.x. Epub 2008 Apr 1. Liver Int. 2009. PMID: 18384519 Clinical Trial.
89 results